InnovHeart s.r.l. is a medical device company specializing in the development of transcatheter mitral valve replacement (TMVR) systems aimed at treating mitral valve disease. Founded in 2015 and headquartered in Milan, Italy, with an additional office in Newton, Massachusetts, InnovHeart has created the Saturn TMVR system, which is designed for both trans-apical and trans-septal delivery. The company is currently conducting clinical trials to further validate this innovative technology. By focusing on user-friendly transcatheter solutions, InnovHeart aims to provide safe and effective treatment options for patients suffering from heart valve dysfunction.
CYSEC is a startup working on next generation Confidential Computing solutions securing data at rest, in motion and in use. Currently they have released their ARCA solution which is quickly becoming one of the more popular choices in the market.
CellPly s.r.l., founded in 2013 and based in Bologna, Italy, specializes in developing diagnostic tools aimed at personalizing cancer treatment. The company’s platform allows clinicians and researchers to analyze small ex-vivo samples and rare cells immediately after collection from patients while preserving the microenvironment. This technology provides critical insights into tumor cell sensitivity to drugs and the in-vivo status of immune cells near tumors. By facilitating the selection of optimal treatment options for oncologists and aiding scientists in studying cellular responses to therapies, CellPly's solutions contribute significantly to enhancing the efficacy of immunotherapies and chemotherapies. Furthermore, pharmaceutical companies can utilize these tools for patient stratification, potentially increasing drug effectiveness and rehabilitating less effective treatments.
Cortilia S.p.A. is a prominent online food retailer based in Milan, Italy, specializing in fresh and artisanal products. Founded in 2011, the company connects consumers with local farmers and producers, offering a diverse range of items including fruits, vegetables, meats, dairy products, ready meals, pasta, bread, desserts, and beverages. Cortilia emphasizes sustainability by delivering seasonal products directly to customers' homes, ensuring quality and freshness. In addition to its core offerings, the company provides food storage services to enhance the customer experience. With operations extending to Milan, Turin, and Bologna, Cortilia has established itself as a leader in the Italian online food retail market.
WISE Srl, established in 2011 and headquartered in Milan, Italy, specializes in the manufacture of implantable biomedical devices for biotechnology and biomedicine applications. The company employs advanced supersonic cluster beam implantation technology to integrate biocompatible, flexible, and stretchable conductive micro-electrodes into polymers, particularly elastomers. This innovative approach is primarily utilized in developing leads for neurostimulation, which are implanted in the spinal cord or brain to address neurodegenerative conditions such as chronic pain and Parkinson's disease. WISE aims to create a new generation of neuromodulation leads that are unbreakable, less invasive, and more cost-effective, enhancing treatment options for patients.
InnovHeart s.r.l. is a medical device company specializing in the development of transcatheter mitral valve replacement (TMVR) systems aimed at treating mitral valve disease. Founded in 2015 and headquartered in Milan, Italy, with an additional office in Newton, Massachusetts, InnovHeart has created the Saturn TMVR system, which is designed for both trans-apical and trans-septal delivery. The company is currently conducting clinical trials to further validate this innovative technology. By focusing on user-friendly transcatheter solutions, InnovHeart aims to provide safe and effective treatment options for patients suffering from heart valve dysfunction.
Enthera S.r.l. is an Italian biotechnology company established in 2016, based in Milan, and operates as a subsidiary of BiovelocITA S.r.l. The company focuses on developing innovative biologics aimed at treating diabetes and its related gastrointestinal complications, particularly enteropathy, as well as other intestinal disorders that share similar biological pathways. Enthera's research is centered on monoclonal antibody discovery and biotherapeutics that target mechanisms involved in cell apoptosis in the gut, pancreas, and other organs. By addressing these pathways, Enthera aims to provide effective treatments for underserved autoimmune conditions, thereby contributing to advancements in the management of type 1 diabetes and inflammatory bowel disease. The company's name reflects its mission, combining the terms "entero," relating to the intestine, and "therapy."
Expert.ai specializes in cognitive computing software that utilizes artificial intelligence algorithms to understand and process written language. The company offers a range of products, including its flagship Cogito technology, which supports natural language understanding and machine learning to enhance business processes and decision-making. Key offerings include Cogito Discover for text analytics, Cogito for Claims to automate insurance management, and Cogito for Underwriting to improve risk assessment in insurance. Expert.ai also provides solutions for various sectors such as banking, insurance, life sciences, media, and public administration, along with tools for customer support and biomedical research. Founded in 1989 and headquartered in Modena, Italy, Expert.ai operates internationally, serving clients across Europe, the Americas, and the Middle East.
D-Orbit S.r.l. is an Italian company that specializes in satellite solutions, focusing on the design, development, launch, commissioning, and decommissioning of satellites. Founded in 2011 and headquartered in Sesto Fiorentino, Italy, D-Orbit aims to provide innovative technologies for the safe disposal of artificial satellites at the end of their operational life, thereby reducing space debris. The company serves satellite owners and operators, offering products and services that enhance the efficiency and reliability of satellite missions while minimizing costs. D-Orbit also emphasizes the social and environmental benefits of its solutions, striving to streamline all phases of satellite operations. With approximately 35 employees, D-Orbit has expanded its reach with subsidiaries in Washington, DC, and Lisbon, Portugal.
D-Orbit S.r.l. is an Italian company that specializes in satellite solutions, focusing on the design, development, launch, commissioning, and decommissioning of satellites. Founded in 2011 and headquartered in Sesto Fiorentino, Italy, D-Orbit aims to provide innovative technologies for the safe disposal of artificial satellites at the end of their operational life, thereby reducing space debris. The company serves satellite owners and operators, offering products and services that enhance the efficiency and reliability of satellite missions while minimizing costs. D-Orbit also emphasizes the social and environmental benefits of its solutions, striving to streamline all phases of satellite operations. With approximately 35 employees, D-Orbit has expanded its reach with subsidiaries in Washington, DC, and Lisbon, Portugal.
Intrepida Bio, Inc., a biotechnology company, develops cancer drugs that alter the body’s first line of defense, and innate immunity. It also discovers and develops medicines that modulate the innate immune system to fight cancer and other diseases; and develops monoclonal antibodies that block the novel targets BAG3 and its receptor IFITM-2 to thwart their ability to create a favorable environment for tumor growth. Intrepida Bio, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
Newronika s.r.l. is a Milan-based company that specializes in the development and marketing of neuromodulation systems aimed at addressing brain-related issues. Founded in 2016, it offers innovative therapeutic tools, including the WebBioBank platform, which utilizes transcranial direct current stimulation (tDCS) for long-lasting functional changes in the cerebral cortex, targeting conditions such as chronic pain, depression, and stroke rehabilitation. The HDCkit system, featuring a programmer, stimulator, and standard electrodes, ensures effective and safe stimulation for patients. As a spin-off from prominent research institutions in Italy, Newronika combines expertise from various scientific fields, including neurophysiology and biomedical engineering, to enhance treatment methodologies. The company distributes its products in the United Kingdom and internationally, aiming to improve patient quality of life through precise neuro-stimulation.
Cortilia S.p.A. is a prominent online food retailer based in Milan, Italy, specializing in fresh and artisanal products. Founded in 2011, the company connects consumers with local farmers and producers, offering a diverse range of items including fruits, vegetables, meats, dairy products, ready meals, pasta, bread, desserts, and beverages. Cortilia emphasizes sustainability by delivering seasonal products directly to customers' homes, ensuring quality and freshness. In addition to its core offerings, the company provides food storage services to enhance the customer experience. With operations extending to Milan, Turin, and Bologna, Cortilia has established itself as a leader in the Italian online food retail market.
BiovelocITA brings together best-in-class scientists, entrepreneurs and investors to foster the development of pioneering companies. BiovelocITA is co-founded and promoted by Sofinnova Partners, a historical player on the Italian biotech market. Active in Italy for more than fifteen years, Sofinnova Partners is in a privileged position to help Italy grow into one of Europe’s strongest biotech market.
UltraSoC Technologies Ltd. specializes in semiconductor intellectual property (IP) focused on system monitoring, analysis, and optimization for advanced systems-on-chip (SoC) devices. Founded in 2005 and headquartered in Cambridge, UK, the company offers a comprehensive toolkit that includes dedicated and optimized IP, as well as configurable modules for design-time and run-time adjustment. Its technology facilitates non-intrusive, wire-speed monitoring of SoC behavior, allowing engineers to understand complex interactions among on-chip subsystems, buses, and software. This capability accelerates development and minimizes risks associated with SoC design. UltraSoC's solutions are applied in various contexts, including SoC debugging, analytics, optimization, and security applications, thereby enhancing the efficiency of embedded systems development. The company operates as a subsidiary of Siemens Aktiengesellschaft.
MainStreaming SpA is a video delivery network that specializes in cloud-based video hosting and streaming services. Founded in 2015 and headquartered in Milan, Italy, with additional offices in major cities like San Francisco, New York, and London, the company provides a platform for live and on-demand video content delivery. Its technology integrates all operational phases, including ingest, encoding, management, and distribution, ensuring high-quality streaming experiences for broadcasters, media, and gaming companies. MainStreaming offers customizable video players, an API for developers, and real-time media delivery solutions that effectively manage high traffic during live events. The company serves a diverse range of industries, including online media, corporate video, and education, while also providing consulting services to assist clients with online video distribution and performance monitoring.
Sweetguest s.r.l., founded in 2016 and based in Milan, Italy, specializes in providing comprehensive management services for short-term rental properties. The company has developed a mobile application that streamlines the reservation process and offers a full range of services to both property owners and their guests. Sweetguest manages all aspects of short-term rentals, including reservations, check-ins, check-outs, laundry, and cleaning. By handling these tasks, Sweetguest enables property owners to maximize their earnings while saving time and effort, ensuring a high-quality experience for everyone involved.
Talent Garden is a prominent innovation platform and coworking network that supports digital and technology professionals. Established in 2011 in Brescia, Italy, the company operates 23 campuses across eight countries, including Albania, Austria, Denmark, Ireland, Italy, Lithuania, Romania, and Spain. Talent Garden serves as a collaborative environment for startups, freelancers, and large corporations, fostering connections and professional development within the digital and tech sectors. The organization aims to cultivate vibrant, locally connected campuses that empower communities and enhance the growth of innovative ideas. With a growing membership of over 600 talents and more than 40,000 online community members, Talent Garden is dedicated to creating an ecosystem that nurtures entrepreneurial success and collaboration among professionals in the technology space.
Travel Appeal is a technology company based in Florence, Italy, that specializes in providing data-driven insights for the travel industry. Established in 2014, the company utilizes artificial intelligence to monitor and analyze vast amounts of geographical data, online feedback, and customer purchasing behaviors in real time. Its platform processes this information through proprietary algorithms and a semantic engine, delivering actionable insights to help businesses enhance their online reputation, optimize pricing strategies, and improve overall performance. Travel Appeal offers its services through various delivery methods, including API, mobile applications, and dashboards, catering to different levels of travel professionals. Its solutions are designed to assist hotels, restaurants, museums, and destinations in maximizing customer experiences and staying competitive in the market.
Bendit Technologies Ltd. is a medical company specializing in the development and manufacturing of innovative catheters that utilize a unique bending technology to enhance steering capabilities in both micro and conventional catheter wires. Founded in 2013 and headquartered in Petach Tikva, Israel, the company focuses on creating small and flexible microcatheters designed for optimal navigation through vessels with complex anatomies. Bendit's products aim to improve the precision of medical procedures by enabling doctors to direct the catheters effectively, thereby minimizing risks and enhancing success rates. The company's expertise is bolstered by a joint venture of experienced professionals from production, quality, regulation, and development sectors within the medical field.
Easy Rain’s mission is to improve the safety of wheel vehicles, by contrasting a problem has not currently been addressed by any safety device, being the hydroplaning phenomenon. Hydroplaning is a phenomenon that causes loss of traction between a vehicle’s wheels and the roads surface due to the presence of a layer of water. Millions of accidents every year on wet roads. Also Autonomous driving technology has a big issue with wet roads. Easy Rain developed, tested, validated and patented a new driver assistance system specifically designed to contrast hydroplaning. The system prevents large amounts of water from touching the tire, thereby improving a vehicle’s performance and safety, by increasing the adherence of the tire on wet surfaces.
Bendit Technologies Ltd. is a medical company specializing in the development and manufacturing of innovative catheters that utilize a unique bending technology to enhance steering capabilities in both micro and conventional catheter wires. Founded in 2013 and headquartered in Petach Tikva, Israel, the company focuses on creating small and flexible microcatheters designed for optimal navigation through vessels with complex anatomies. Bendit's products aim to improve the precision of medical procedures by enabling doctors to direct the catheters effectively, thereby minimizing risks and enhancing success rates. The company's expertise is bolstered by a joint venture of experienced professionals from production, quality, regulation, and development sectors within the medical field.
UltraSoC Technologies Ltd. specializes in semiconductor intellectual property (IP) focused on system monitoring, analysis, and optimization for advanced systems-on-chip (SoC) devices. Founded in 2005 and headquartered in Cambridge, UK, the company offers a comprehensive toolkit that includes dedicated and optimized IP, as well as configurable modules for design-time and run-time adjustment. Its technology facilitates non-intrusive, wire-speed monitoring of SoC behavior, allowing engineers to understand complex interactions among on-chip subsystems, buses, and software. This capability accelerates development and minimizes risks associated with SoC design. UltraSoC's solutions are applied in various contexts, including SoC debugging, analytics, optimization, and security applications, thereby enhancing the efficiency of embedded systems development. The company operates as a subsidiary of Siemens Aktiengesellschaft.
Directa Plus S.p.A. is a nanotechnology company based in Lomazzo, Italy, specializing in the production and supply of graphene-based products for various industrial and commercial applications. Founded in 2005, the company operates through several segments, including Textile, Environmental, and Others, offering a diverse range of products under the G+ brand name. Its graphene-based solutions are utilized in elastomers, smart textiles, wastewater treatment, polymer nanocomposites, and more. The environmental segment generates a significant portion of the company's revenue, reflecting its commitment to innovative applications such as oil-spill recovery and water treatment. Directa Plus aims to provide high-quality engineered products that enhance the performance of consumer and industrial goods.
CellPly s.r.l., founded in 2013 and based in Bologna, Italy, specializes in developing diagnostic tools aimed at personalizing cancer treatment. The company’s platform allows clinicians and researchers to analyze small ex-vivo samples and rare cells immediately after collection from patients while preserving the microenvironment. This technology provides critical insights into tumor cell sensitivity to drugs and the in-vivo status of immune cells near tumors. By facilitating the selection of optimal treatment options for oncologists and aiding scientists in studying cellular responses to therapies, CellPly's solutions contribute significantly to enhancing the efficacy of immunotherapies and chemotherapies. Furthermore, pharmaceutical companies can utilize these tools for patient stratification, potentially increasing drug effectiveness and rehabilitating less effective treatments.